WO2002022571A3 - Composes et procedes pour l'inhibition d'integrines alpha-1 beta-1 - Google Patents

Composes et procedes pour l'inhibition d'integrines alpha-1 beta-1 Download PDF

Info

Publication number
WO2002022571A3
WO2002022571A3 PCT/US2001/028522 US0128522W WO0222571A3 WO 2002022571 A3 WO2002022571 A3 WO 2002022571A3 US 0128522 W US0128522 W US 0128522W WO 0222571 A3 WO0222571 A3 WO 0222571A3
Authority
WO
WIPO (PCT)
Prior art keywords
integrins
beta
compounds
methods
obtustatin
Prior art date
Application number
PCT/US2001/028522
Other languages
English (en)
Other versions
WO2002022571A2 (fr
Inventor
Cezary Marcinkiewicz
Original Assignee
Univ Temple
Cezary Marcinkiewicz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple, Cezary Marcinkiewicz filed Critical Univ Temple
Priority to AU2001294552A priority Critical patent/AU2001294552A1/en
Priority to EP01975200A priority patent/EP1322322A4/fr
Priority to CA002421786A priority patent/CA2421786A1/fr
Publication of WO2002022571A2 publication Critical patent/WO2002022571A2/fr
Publication of WO2002022571A3 publication Critical patent/WO2002022571A3/fr
Priority to US10/386,055 priority patent/US20030186334A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne l'obtustatine, une disintégrine courte indéprendante de la séquence RGD (arginine-glycine-acide aspartique), qui a une action inhibitrice puissante et sélective sur la liaison de l'intégrine α1β1 avec son ligand d'adhésion. On peut utiliser l'obtustatine, y compris ses fragments, dérives, homologues et analogues, pour le traitement des maladies et pour moduler les états biologiques associés à l'intégrine α1β1.
PCT/US2001/028522 2000-09-11 2001-09-12 Composes et procedes pour l'inhibition d'integrines alpha-1 beta-1 WO2002022571A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001294552A AU2001294552A1 (en) 2000-09-11 2001-09-12 Compounds and methods for inhibiting alpha-1 beta-1 integrins
EP01975200A EP1322322A4 (fr) 2000-09-11 2001-09-12 Composes et procedes pour l'inhibition d'integrines alpha-1 beta-1
CA002421786A CA2421786A1 (fr) 2000-09-11 2001-09-12 Composes et procedes pour l'inhibition d'integrines alpha-1 beta-1
US10/386,055 US20030186334A1 (en) 2001-09-12 2003-03-11 KTS-disintegrins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23159100P 2000-09-11 2000-09-11
US60/231,591 2000-09-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/386,055 Continuation-In-Part US20030186334A1 (en) 2001-09-12 2003-03-11 KTS-disintegrins

Publications (2)

Publication Number Publication Date
WO2002022571A2 WO2002022571A2 (fr) 2002-03-21
WO2002022571A3 true WO2002022571A3 (fr) 2002-06-20

Family

ID=22869882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/028522 WO2002022571A2 (fr) 2000-09-11 2001-09-12 Composes et procedes pour l'inhibition d'integrines alpha-1 beta-1

Country Status (4)

Country Link
EP (1) EP1322322A4 (fr)
AU (1) AU2001294552A1 (fr)
CA (1) CA2421786A1 (fr)
WO (1) WO2002022571A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016883A2 (fr) * 2003-08-14 2005-02-24 Icos Corporation Derives d'acrylamide servant d'antagonistes de l'integrine vla-1, et leurs utilisations
WO2015087334A1 (fr) 2013-12-15 2015-06-18 Yissum Research Develoment Company Of The Hebrew University Of Jerusalem Ltd. Peptides dérivés de vipéristatine et leurs utilisations
MA49645A (fr) * 2017-07-20 2021-03-31 Univ Virginia Patent Foundation Procédés de traitement ou de prévention d'un trouble neurologique du système immunitaire
CN110974938A (zh) * 2019-12-02 2020-04-10 上海长海医院 整合素α1β1抑制剂在制备预防或治疗主动脉疾病药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACTA CHEM. SCAND., vol. 19, no. 7, 1965, pages 1566 - 1574 *
DATABASE HCAPLUS [online] CHEMICAL ABSTRACTS SERVICE (COLUMBUS, OHIO, USA); FOLSCH G. ET AL.: "Hydrolysis of phosphopeptides. II. Leucine aminopeptidase hydrolysis of free and O-phosphorylated serine peptides", XP002909243, accession no. STN Database accession no. 1966:28765 *
See also references of EP1322322A4 *

Also Published As

Publication number Publication date
WO2002022571A2 (fr) 2002-03-21
AU2001294552A1 (en) 2002-03-26
EP1322322A4 (fr) 2005-04-06
CA2421786A1 (fr) 2002-03-21
EP1322322A2 (fr) 2003-07-02

Similar Documents

Publication Publication Date Title
PL369096A1 (en) Absorbent wound dressing containing a hydrogel layer
WO2004080430A3 (fr) Procedes pour ameliorer la qualite de la peau
DE69932996D1 (de) Verschlussvorrichtung für Kathetereingriff, sowie Kathetereinrichtung dafür
WO2005107730A3 (fr) Matieres et procedes de modulation du metabolisme
WO2000061167A3 (fr) TRAITEMENT DU SYNDROME MYELOPROLIFERATIF AU MOYEN D'INHIBITEURS DE L'ACTIVITE DES PROTEASOMES ET DE NF-λB
WO2001086002A3 (fr) Compositions, kits, et procedes pour l'identification, l'evaluation, la prevention, et la therapie du psoriasis
WO2004056308A3 (fr) Anticorps chimeriques et humanises diriges contre l'integrine $g(a)5$g(b)1 modulant l'angiogenese
HK1070004A1 (en) Methods for treating rosacea and telangiectasia
MXPA05000122A (es) Compuestos utiles para la inhibicion de aldehido-deshidrogenasa.
WO2001078703A3 (fr) Methodes et compositions destinees a moduler l'activite des recepteurs adrenergiques alpha
WO2005044194A3 (fr) Traitement ou prevention de la neoplasie a l'aide d'un inhibiteur de la proteine hsp90
WO2008115870A3 (fr) Induction et/ou maintenance d'une dormance de tumeur par rupture de l'interaction récepteur d'activateur du plasminogène d'urokinase-intégrine
WO2007131047A3 (fr) Formulations topiques contenant le co-enzyme q10 et traitement de la douleur, de la fatigue et des plaies
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
TW200716193A (en) Skin regeneration promoter
WO2002037927A3 (fr) Composes et procedes servant a faciliter l'arret du tabac
WO2004053101A3 (fr) Methodes et compositions utilisant des composes tires de cellules et de tissus foetaux pour ameliorer l'etat de la peau
AU2003228796A1 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
EP1667685A4 (fr) Inhibiteurs du canal potassique a base de quinazoline
WO2008067158A3 (fr) MÉTHODE DESTINÉE À FAVORISER LA POUSSE DES CHEVEUX ET/OU À RETARDER OU TRAITER LA CHUTE DES CHEVEUX PAR ADMINISTRATION D'UN ANTAGONISTE OU D'UN INHIBITEUR DU TGF-β
WO2002022571A3 (fr) Composes et procedes pour l'inhibition d'integrines alpha-1 beta-1
HRPK20010442B1 (en) Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
EP1667976A4 (fr) Inhibiteurs du canal potassique a base d'isoquinolinone
BRPI0511323A (pt) tetraidroisoquinolinas substituìdas usadas na forma de inibidores de mmp, método para a produção e uso das mesmas na forma de drágeas
WO2003051290A3 (fr) Traitement de maladies mediees par les lymphocytes b par modulation de l'activite du dr6

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2421786

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10386055

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001975200

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001975200

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001975200

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP